BioNTech Results Presentation Deck
Expanded clinical stage pipeline to 12 product candidates across 13 trials
Drug
class
mRNA
Antibodies
SMIM6
Platform
Fix Vac
(fixed combination of
shared cancer antigens)
iNeST
(patient specific cancer
antigen therapy)
Intratumoral
Immunotherapy
Infectious Disease
Immunotherapy
Next-Gen CP²
Immunomodulators
Targeted Cancer
Antibodies
Toll-Like
Receptor Binding
Product
Candidate
BNT111
BNT112
BNT113
BNT114
BNT115
RO7198457
(BNT1224)
SAR441000
(BNT131)
BNT 162
GEN1046
(BNT311)
GEN1042
(BNT312)
BNT321
(MVT-5873)
BNT411
Indication (Targets)
advanced melanoma
(adjuvant & metastatic)
prostate cancer
HPV16+ head and neck cancer¹
triple negative breast cancer4
ovarian cancer¹
1L melanoma with CP12
multiple solid tumors
solid tumors (IL-12sc,
IL-15sushi, GM-CSF, IFN a)
COVID-19
multiple solid tumors
(PD-L1x4-1BB)
multiple solid tumors
(CD40×4-1BB)
pancreatic cancer (sLea)
solid tumors (TLR7)
Rights /
Preclinical Phase 1 Phase 2 Collaborator
fully-owned
(Regeneron)
fully-owned
fully-owned
fully-owned
fully-owned
Genentech
(global 50:50
profit/loss)
Sanofi (global profit/
loss share)
Pfizer/Fosun
Genmab
(global 50:50
profit/loss)
fully-owned
fully-owned
1 BNT113 and BNT115 are currently being studied in investigator-initiated phase 1 trials; 2 Checkpoint Inhibitor; 3 Update on the ongoing study including patient enrollment number, efficacy and
safety data for an interim update expected in the second half of 2021; 4 BNT122 (iNeST) is also being investigated in arm 2 (N=15) of the 3 arm TNBC-MERIT trial, with BNT114 as an optional
treatment; BNT114 is investigated in arm 1 (N=12) and arm 3 (N=15) of the TNBC-MERIT trial (total patients in study: N=42); 5 As the trial is sponsored and conducted by Sanofi, the timing of
data updates is not under our control, and is subject to change by Sanofi; Small Molecule Immunomodulators
9
1
i BNT111 Fix Vac Melanoma data
in Nature and Regeneron
collaboration
2
3
! Update for anti-PDL1x4-1BB bi-
specific antibody expected in 2H
I 2020
4
iNeST AACR Phase 1 data update
and planned Phase 2 trials in
adjuvant NSCLC and CRC
I
Initiation of Phase 1/2 trial for
TLR-7 agonist in ES-SCLC
BIONTECH
IView entire presentation